MedTrace Logo

Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)

NCT02430194 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2023-03-03

Study results available
· View outcomes & findings →

Summary

An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).

Conditions

  • Chronic Hepatitis D Infection

Interventions

DRUG

lonafarnib

antiviral farnesyl transferase inhibitor

DRUG

ritonavir

CYP 3A4 inhibitor, lonafarnib booster

DRUG

Pegylated interferon-alfa-2a

immunomodulator

Sponsors & Collaborators

  • Ankara University

    collaborator OTHER

  • Eiger BioPharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Cihan Yurdaydin, MD · Ankara University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-04-18
Completion
2017-06-15
FDA Drug
Yes

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430194 on ClinicalTrials.gov